-
1
-
-
85007302654
-
AAV2 gene therapy readministration in three adults with congenital blindness
-
Bennett, J., Ashtari, M., Wellman, J., Marshall, K.A., Cyckowski, L.L., Chung, D.C., Mccague, S., Pierce, E.A., Chen, Y., Bennicelli, J.L., Zhu, X., Ying, G.S., Sun, J., Wright, J.F., Auricchio, A., Simonelli, F., Shindler, K.S., Mingozzi, F., High, K.A., Maguire, A.M., AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 4, 2012, 120ra15.
-
(2012)
Sci. Transl. Med.
, vol.4
, pp. 120ra15
-
-
Bennett, J.1
Ashtari, M.2
Wellman, J.3
Marshall, K.A.4
Cyckowski, L.L.5
Chung, D.C.6
Mccague, S.7
Pierce, E.A.8
Chen, Y.9
Bennicelli, J.L.10
Zhu, X.11
Ying, G.S.12
Sun, J.13
Wright, J.F.14
Auricchio, A.15
Simonelli, F.16
Shindler, K.S.17
Mingozzi, F.18
High, K.A.19
Maguire, A.M.20
more..
-
2
-
-
0021827230
-
Long-term diabetic vitrectomy results. Report of 10 year follow-up
-
Blankenship, G.W., Machemer, R., Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 92 (1985), 503–506.
-
(1985)
Ophthalmology
, vol.92
, pp. 503-506
-
-
Blankenship, G.W.1
Machemer, R.2
-
3
-
-
0036300131
-
PEDF: anti-angiogenic guardian of ocular function
-
Bouck, N., PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. 8 (2002), 330–334.
-
(2002)
Trends Mol. Med.
, vol.8
, pp. 330-334
-
-
Bouck, N.1
-
4
-
-
1842530296
-
Causes and prevalence of visual impairment among adults in the United States
-
Congdon, N., O'Colmain, B., Klaver, C.C., Klein, R., Munoz, B., Friedman, D.S., Kempen, J., Taylor, H.R., Mitchell, P., Eye Diseases Prevalence Research, G., Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122 (2004), 477–485.
-
(2004)
Arch. Ophthalmol.
, vol.122
, pp. 477-485
-
-
Congdon, N.1
O'Colmain, B.2
Klaver, C.C.3
Klein, R.4
Munoz, B.5
Friedman, D.S.6
Kempen, J.7
Taylor, H.R.8
Mitchell, P.9
Eye Diseases Prevalence Research, G.10
-
5
-
-
79956218863
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
-
CATT Research Group, Martin, D.F., Maguire, M.G., Ying, G.S., Grunwald, J.E., Fine, S.L., Jaffe, G.J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364 (2011), 1897–1908.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 1897-1908
-
-
CATT Research Group1
Martin, D.F.2
Maguire, M.G.3
Ying, G.S.4
Grunwald, J.E.5
Fine, S.L.6
Jaffe, G.J.7
-
6
-
-
84870723704
-
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
-
Heier, J.S., Brown, D.M., Chong, V., Korobelnik, J.F., Kaiser, P.K., Nguyen, Q.D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Groetzbach, G., Sommerauer, B., Sandbrink, R., Simader, C., Schmidt-Erfurth, U., View & Groups, V. S, Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
-
(2012)
Ophthalmology
, vol.119
, pp. 2537-2548
-
-
Heier, J.S.1
Brown, D.M.2
Chong, V.3
Korobelnik, J.F.4
Kaiser, P.K.5
Nguyen, Q.D.6
Kirchhof, B.7
Ho, A.8
Ogura, Y.9
Yancopoulos, G.D.10
Stahl, N.11
Vitti, R.12
Berliner, A.J.13
Soo, Y.14
Anderesi, M.15
Groetzbach, G.16
Sommerauer, B.17
Sandbrink, R.18
Simader, C.19
Schmidt-Erfurth, U.20
View & Groups, V. S,21
more..
-
7
-
-
0037143764
-
VEGF-trap: a VEGF blocker with potent antitumor effects
-
Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J.P., Daly, T., Wiegand, S.J., Yancopoulos, G.D., Rudge, J.S., VEGF-trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 11393–11398.
-
(2002)
Proc. Natl. Acad. Sci. U. S. A.
, vol.99
, pp. 11393-11398
-
-
Holash, J.1
Davis, S.2
Papadopoulos, N.3
Croll, S.D.4
Ho, L.5
Russell, M.6
Boland, P.7
Leidich, R.8
Hylton, D.9
Burova, E.10
Ioffe, E.11
Huang, T.12
Radziejewski, C.13
Bailey, K.14
Fandl, J.P.15
Daly, T.16
Wiegand, S.J.17
Yancopoulos, G.D.18
Rudge, J.S.19
-
8
-
-
84863327423
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial
-
IVAN Study Investigators, Chakravarthy, U., Harding, S.P., Rogers, C.A., Downes, S.M., Lotery, A.J., Wordsworth, S., Reeves, B.C., Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119 (2012), 1399–1411.
-
(2012)
Ophthalmology
, vol.119
, pp. 1399-1411
-
-
IVAN Study Investigators1
Chakravarthy, U.2
Harding, S.P.3
Rogers, C.A.4
Downes, S.M.5
Lotery, A.J.6
Wordsworth, S.7
Reeves, B.C.8
-
9
-
-
36249002808
-
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results
-
Kaiser, P.K., Brown, D.M., Zhang, K., Hudson, H.L., Holz, F.G., Shapiro, H., Schneider, S., Acharya, N.R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J. Ophthalmol. 144 (2007), 850–857.
-
(2007)
Am J. Ophthalmol.
, vol.144
, pp. 850-857
-
-
Kaiser, P.K.1
Brown, D.M.2
Zhang, K.3
Hudson, H.L.4
Holz, F.G.5
Shapiro, H.6
Schneider, S.7
Acharya, N.R.8
-
10
-
-
0027421333
-
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
-
Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10705–10709.
-
(1993)
Proc. Natl. Acad. Sci. U. S. A.
, vol.90
, pp. 10705-10709
-
-
Kendall, R.L.1
Thomas, K.A.2
-
11
-
-
0031050126
-
Increased expression of angiogenic growth factors in age-related maculopathy
-
Kliffen, M., Sharma, H.S., Mooy, C.M., Kerkvliet, S., De Jong, P.T., Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81 (1997), 154–162.
-
(1997)
Br. J. Ophthalmol.
, vol.81
, pp. 154-162
-
-
Kliffen, M.1
Sharma, H.S.2
Mooy, C.M.3
Kerkvliet, S.4
De Jong, P.T.5
-
12
-
-
0034919401
-
Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization
-
Lai, C.M., Brankov, M., Zaknich, T., Lai, Y.K., Shen, W.Y., Constable, I.J., Kovesdi, I., Rakoczy, P.E., Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12 (2001), 1299–1310.
-
(2001)
Hum. Gene Ther.
, vol.12
, pp. 1299-1310
-
-
Lai, C.M.1
Brankov, M.2
Zaknich, T.3
Lai, Y.K.4
Shen, W.Y.5
Constable, I.J.6
Kovesdi, I.7
Rakoczy, P.E.8
-
13
-
-
84867403190
-
Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates
-
Lai, C.M., Estcourt, M.J., Himbeck, R.P., Lee, S.Y., Yew-San Yeo, I., Luu, C., Loh, B.K., Lee, M.W., Barathi, A., Villano, J., Ang, C.L., Van Der Most, R.G., Constable, I.J., Dismuke, D., Samulski, R.J., Degli-Esposti, M.A., Rakoczy, E.P., Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 19 (2012), 999–1009.
-
(2012)
Gene Ther.
, vol.19
, pp. 999-1009
-
-
Lai, C.M.1
Estcourt, M.J.2
Himbeck, R.P.3
Lee, S.Y.4
Yew-San Yeo, I.5
Luu, C.6
Loh, B.K.7
Lee, M.W.8
Barathi, A.9
Villano, J.10
Ang, C.L.11
Van Der Most, R.G.12
Constable, I.J.13
Dismuke, D.14
Samulski, R.J.15
Degli-Esposti, M.A.16
Rakoczy, E.P.17
-
14
-
-
70349230977
-
rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector
-
Lai, C.M., Estcourt, M.J., Wikstrom, M., Himbeck, R.P., Barnett, N.L., Brankov, M., Tee, L.B., Dunlop, S.A., Degli-Esposti, M.A., Rakoczy, E.P., rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest. Ophthalmol. Vis. Sci. 50 (2009), 4279–4287.
-
(2009)
Invest. Ophthalmol. Vis. Sci.
, vol.50
, pp. 4279-4287
-
-
Lai, C.M.1
Estcourt, M.J.2
Wikstrom, M.3
Himbeck, R.P.4
Barnett, N.L.5
Brankov, M.6
Tee, L.B.7
Dunlop, S.A.8
Degli-Esposti, M.A.9
Rakoczy, E.P.10
-
15
-
-
25144485909
-
Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys
-
Lai, C.M., Shen, W.Y., Brankov, M., Lai, Y.K., Barnett, N.L., Lee, S.Y., Yeo, I.Y., Mathur, R., Ho, J.E., Pineda, P., Barathi, A., Ang, C.L., Constable, I.J., Rakoczy, E.P., Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. 12 (2005), 659–668.
-
(2005)
Mol. Ther.
, vol.12
, pp. 659-668
-
-
Lai, C.M.1
Shen, W.Y.2
Brankov, M.3
Lai, Y.K.4
Barnett, N.L.5
Lee, S.Y.6
Yeo, I.Y.7
Mathur, R.8
Ho, J.E.9
Pineda, P.10
Barathi, A.11
Ang, C.L.12
Constable, I.J.13
Rakoczy, E.P.14
-
16
-
-
0347532850
-
Virus-mediated secretion gene therapy – a potential treatment for ocular neovascularization
-
Lai, Y.K., Sharma, S., Lai, C.M., Brankov, M., Constable, I.J., Rakoczy, P.E., Virus-mediated secretion gene therapy – a potential treatment for ocular neovascularization. Adv. Exp. Med. Biol. 533 (2003), 447–453.
-
(2003)
Adv. Exp. Med. Biol.
, vol.533
, pp. 447-453
-
-
Lai, Y.K.1
Sharma, S.2
Lai, C.M.3
Brankov, M.4
Constable, I.J.5
Rakoczy, P.E.6
-
17
-
-
0036083592
-
Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy
-
Lai, Y.K., Shen, W.Y., Brankov, M., Lai, C.M., Constable, I.J., Rakoczy, P.E., Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9 (2002), 804–813.
-
(2002)
Gene Ther.
, vol.9
, pp. 804-813
-
-
Lai, Y.K.1
Shen, W.Y.2
Brankov, M.3
Lai, C.M.4
Constable, I.J.5
Rakoczy, P.E.6
-
18
-
-
67149101784
-
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study
-
e1
-
Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy, S.R., Michels, S., Feuer, W., Davis, J.L., Flynn, H.W. Jr., Esquiabro, M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J. Ophthalmol. 148 (2009), 43–58, e1.
-
(2009)
Am J. Ophthalmol.
, vol.148
, pp. 43-58
-
-
Lalwani, G.A.1
Rosenfeld, P.J.2
Fung, A.E.3
Dubovy, S.R.4
Michels, S.5
Feuer, W.6
Davis, J.L.7
Flynn, H.W.8
Esquiabro, M.9
-
19
-
-
54549125880
-
Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential
-
Li, Q., Miller, R., Han, P.Y., Pang, J., Dinculescu, A., Chiodo, V., Hauswirth, W.W., Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14 (2008), 1760–1769.
-
(2008)
Mol. Vis.
, vol.14
, pp. 1760-1769
-
-
Li, Q.1
Miller, R.2
Han, P.Y.3
Pang, J.4
Dinculescu, A.5
Chiodo, V.6
Hauswirth, W.W.7
-
20
-
-
84879298265
-
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
-
e00324
-
Luo, L., Uehara, H., Zhang, X., Das, S.K., Olsen, T., Holt, D., Simonis, J.M., Jackman, K., Singh, N., Miya, T.R., Huang, W., Ahmed, F., Bastos-Carvalho, A., Le, Y.Z., Mamalis, C., Chiodo, V.A., Hauswirth, W.W., Baffi, J., Lacal, P.M., Orecchia, A., Ferrara, N., Gao, G., Young-Hee, K., Fu, Y., Owen, L., Albuquerque, R., Baehr, W., Thomas, K., Li, D.Y., Chalam, K.V., Shibuya, M., Grisanti, S., Wilson, D.J., Ambati, J., Ambati, B.K., Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife, 2, 2013, e00324.
-
(2013)
Elife
, vol.2
-
-
Luo, L.1
Uehara, H.2
Zhang, X.3
Das, S.K.4
Olsen, T.5
Holt, D.6
Simonis, J.M.7
Jackman, K.8
Singh, N.9
Miya, T.R.10
Huang, W.11
Ahmed, F.12
Bastos-Carvalho, A.13
Le, Y.Z.14
Mamalis, C.15
Chiodo, V.A.16
Hauswirth, W.W.17
Baffi, J.18
Lacal, P.M.19
Orecchia, A.20
Ferrara, N.21
Gao, G.22
Young-Hee, K.23
Fu, Y.24
Owen, L.25
Albuquerque, R.26
Baehr, W.27
Thomas, K.28
Li, D.Y.29
Chalam, K.V.30
Shibuya, M.31
Grisanti, S.32
Wilson, D.J.33
Ambati, J.34
Ambati, B.K.35
more..
-
21
-
-
44249085878
-
Safety and efficacy of gene transfer for Leber's congenital amaurosis
-
Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., Rossi, S., Lyubarsky, A., Arruda, V.R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'osso, L., Hertle, R., Ma, J.X., Redmond, T.M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K.S., Maguire, M.G., Wright, J.F., Volpe, N.J., Mcdonnell, J.W., Auricchio, A., High, K.A., Bennett, J., Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2240–2248.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2240-2248
-
-
Maguire, A.M.1
Simonelli, F.2
Pierce, E.A.3
Pugh, E.N.4
Mingozzi, F.5
Bennicelli, J.6
Banfi, S.7
Marshall, K.A.8
Testa, F.9
Surace, E.M.10
Rossi, S.11
Lyubarsky, A.12
Arruda, V.R.13
Konkle, B.14
Stone, E.15
Sun, J.16
Jacobs, J.17
Dell'osso, L.18
Hertle, R.19
Ma, J.X.20
Redmond, T.M.21
Zhu, X.22
Hauck, B.23
Zelenaia, O.24
Shindler, K.S.25
Maguire, M.G.26
Wright, J.F.27
Volpe, N.J.28
Mcdonnell, J.W.29
Auricchio, A.30
High, K.A.31
Bennett, J.32
more..
-
22
-
-
84944339068
-
Gene therapy returns to centre stage
-
Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360.
-
(2015)
Nature
, vol.526
, pp. 351-360
-
-
Naldini, L.1
-
23
-
-
0035173448
-
Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF
-
Ohno-Matsui, K., Morita, I., Tombran-Tink, J., Mrazek, D., Onodera, M., Uetama, T., Hayano, M., Murota, S.I., Mochizuki, M., Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell. Physiol. 189 (2001), 323–333.
-
(2001)
J. Cell. Physiol.
, vol.189
, pp. 323-333
-
-
Ohno-Matsui, K.1
Morita, I.2
Tombran-Tink, J.3
Mrazek, D.4
Onodera, M.5
Uetama, T.6
Hayano, M.7
Murota, S.I.8
Mochizuki, M.9
-
24
-
-
84928599756
-
The status of RPE65 Gene therapy trials: safety and efficacy
-
Pierce, E.A., Bennett, J., The status of RPE65 Gene therapy trials: safety and efficacy. Cold Spring Harb. Perspect. Med., 5, 2015, a017285.
-
(2015)
Cold Spring Harb. Perspect. Med.
, vol.5
, pp. a017285
-
-
Pierce, E.A.1
Bennett, J.2
-
25
-
-
84952639507
-
Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial
-
Rakoczy, E.P., Lai, C.M., Magno, A.L., Wikstrom, M.E., French, M.A., Pierce, C.M., Schwartz, S.D., Blumenkranz, M.S., Chalberg, T.W., Degli-Esposti, M.A., Constable, I.J., Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, 2015.
-
(2015)
Lancet
-
-
Rakoczy, E.P.1
Lai, C.M.2
Magno, A.L.3
Wikstrom, M.E.4
French, M.A.5
Pierce, C.M.6
Schwartz, S.D.7
Blumenkranz, M.S.8
Chalberg, T.W.9
Degli-Esposti, M.A.10
Constable, I.J.11
-
26
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y., Group, M.S., Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006), 1419–1431.
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
Kim, R.Y.7
Group, M.S.8
-
27
-
-
84891631034
-
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies
-
Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.F., Brown, D.M., Chong, V., Nguyen, Q.D., Ho, A.C., Ogura, Y., Simader, C., Jaffe, G.J., Slakter, J.S., Yancopoulos, G.D., Stahl, N., Vitti, R., Berliner, A.J., Soo, Y., Anderesi, M., Sowade, O., Zeitz, O., Norenberg, C., Sandbrink, R., Heier, J.S., Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
-
(2014)
Ophthalmology
, vol.121
, pp. 193-201
-
-
Schmidt-Erfurth, U.1
Kaiser, P.K.2
Korobelnik, J.F.3
Brown, D.M.4
Chong, V.5
Nguyen, Q.D.6
Ho, A.C.7
Ogura, Y.8
Simader, C.9
Jaffe, G.J.10
Slakter, J.S.11
Yancopoulos, G.D.12
Stahl, N.13
Vitti, R.14
Berliner, A.J.15
Soo, Y.16
Anderesi, M.17
Sowade, O.18
Zeitz, O.19
Norenberg, C.20
Sandbrink, R.21
Heier, J.S.22
more..
-
28
-
-
77649242176
-
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration
-
Simonelli, F., Maguire, A.M., Testa, F., Pierce, E.A., Mingozzi, F., Bennicelli, J.L., Rossi, S., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Redmond, T.M., Zhu, X., Shindler, K.S., Ying, G.S., Ziviello, C., Acerra, C., Wright, J.F., Mcdonnell, J.W., High, K.A., Bennett, J., Auricchio, A., Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18 (2010), 643–650.
-
(2010)
Mol. Ther.
, vol.18
, pp. 643-650
-
-
Simonelli, F.1
Maguire, A.M.2
Testa, F.3
Pierce, E.A.4
Mingozzi, F.5
Bennicelli, J.L.6
Rossi, S.7
Marshall, K.8
Banfi, S.9
Surace, E.M.10
Sun, J.11
Redmond, T.M.12
Zhu, X.13
Shindler, K.S.14
Ying, G.S.15
Ziviello, C.16
Acerra, C.17
Wright, J.F.18
Mcdonnell, J.W.19
High, K.A.20
Bennett, J.21
Auricchio, A.22
more..
-
29
-
-
84878581647
-
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2
-
Testa, F., Maguire, A.M., Rossi, S., Pierce, E.A., Melillo, P., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Acerra, C., Wright, J.F., Wellman, J., High, K.A., Auricchio, A., Bennett, J., Simonelli, F., Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
-
(2013)
Ophthalmology
, vol.120
, pp. 1283-1291
-
-
Testa, F.1
Maguire, A.M.2
Rossi, S.3
Pierce, E.A.4
Melillo, P.5
Marshall, K.6
Banfi, S.7
Surace, E.M.8
Sun, J.9
Acerra, C.10
Wright, J.F.11
Wellman, J.12
High, K.A.13
Auricchio, A.14
Bennett, J.15
Simonelli, F.16
-
30
-
-
84920722499
-
The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration
-
Uehara, H., Mamalis, C., Mcfadden, M., Taggart, M., Stagg, B., Passi, S., Earle, P., Chakravarthy, U., Hogg, R.E., Ambati, B.K., The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration. Am J. Ophthalmol. 159:92–100 (2015), e1–e2.
-
(2015)
Am J. Ophthalmol.
, vol.159
, Issue.92-100
, pp. e1-e2
-
-
Uehara, H.1
Mamalis, C.2
Mcfadden, M.3
Taggart, M.4
Stagg, B.5
Passi, S.6
Earle, P.7
Chakravarthy, U.8
Hogg, R.E.9
Ambati, B.K.10
-
31
-
-
84877148806
-
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models
-
e61396
-
Vasireddy, V., Mills, J.A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A.D., Alexandrov, K., Zhou, S., Maguire, A.M., Chung, D.C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J.L., French, D.L., Bennett, J., AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One, 8, 2013, e61396.
-
(2013)
PLoS One
, vol.8
-
-
Vasireddy, V.1
Mills, J.A.2
Gaddameedi, R.3
Basner-Tschakarjan, E.4
Kohnke, M.5
Black, A.D.6
Alexandrov, K.7
Zhou, S.8
Maguire, A.M.9
Chung, D.C.10
Mac, H.11
Sullivan, L.12
Gadue, P.13
Bennicelli, J.L.14
French, D.L.15
Bennett, J.16
|